Navigation Links
SIRO Clinpharm Announces Appointment of Gopakumar Menon as Chief Executive Officer to Lead the Global Clinical Research Organization
Date:3/7/2012

MUMBAI, India, March 7, 2012 /PRNewswire/ --

SIRO Clinpharm, a leading full service Clinical Research Organization announced the appointment of Gopakumar Menon as Chief Executive Officer. SIRO has developed a long term plan to align with the changing dynamics of the biopharma industry, and his primary charter is to transform SIRO into a global leader in the CRO and FSP space. He will be responsible for continuing to build and enhance the biopharma service catalog for SIRO's global delivery model, across the Americas, Europe and Asia.

"It is a pleasure to have Gopakumar on board. Gopakumar brings with him rich experience in driving business growth, and delivering tremendous value for leading companies, including Fortune 1000 companies," said Dr. Gautam Daftary, Chairman of SIRO Clinpharm. "Gopakumar has an excellent track record in cultivating partnership based relationships with Fortune 500 pharmaceutical client base, envisioning cutting-edge business and technical solutions for clients across U.S., Europe, Japan, India, China and Singapore. His experience and knowledge will help SIRO to enhance its services, and build a strong presence in new markets where the company plans to expand its frontiers."

"The biopharma industry is undergoing significant transformations. Clients are actively seeking quality service providers from the emerging markets, who can understand their specific challenges, and partner to build and deliver innovative solutions in a global delivery model," said Gopakumar. "My first priority will be to leverage decades of experience, tremendous value, and geographic reach of SIRO to make it the partner of choice for business critical services of global biopharma leaders. I look forward to working with Gautam and SIRO's board of directors."

Gopakumar has been with the pharmaceutical industry for the more than 12 years, where he worked in various capacities, from discovery to sales and marketing.

Prior to joining SIRO Clinpharm, Gopakumar was with Boston based Sciformix Inc. Gopakumar has had significant experience working with Fortune 500 companies like Cognizant and Satyam, in their Life Sciences divisions, as well as with venture funded start-up organizations.

About SIRO:

SIRO Clinpharm, winner of Frost & Sullivan Indian Clinical Research Organization of the year 2011 award, is a drug development solutions provider to the global healthcare industry. Our subject expertise gives us an edge in data management, medical writing, biostatistics & clinical trial management. Having a successful track record of 16 years, SIRO works with most top global biopharma & medical device companies. Our therapeutic experience includes but is not limited to oncology, diabetes, cardiology, infectious diseases & respiratory system. We offer flexible business models across service verticals based on client needs.

The company has offices in India, Malaysia, USA, and Israel and in Europe at Germany, Romania, Estonia, Greece, Czech Republic and Spain.

For more information please visit our website- http://www.siroclinpharm.com

Media contact:

Ruchi Sanganeria
Corporate Marketing
Tel: +91-22-2584-8000
ruchi.sanganeria@siroclinpharm.com


'/>"/>
SOURCE SIRO Clinpharm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
2. SIRO Clinpharm and CambReg Ltd Strategic Alliance to Offer Regulatory Services in Europe
3. DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm
4. SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
5. SIRO Clinpharm Forms Alliance with Korean CRO DreamCIS
6. SIRO Clinpharms Nimita Limaye Elected as Chairperson of Society for Clinical Data Management (SCDM)
7. SIRO Clinpharm Expands Presence in Asia
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):